To improve the efficacy of immunotherapy in patients with glioblastoma (GBM), the mechanisms behind the phenomenon of why bone marrow T-cell sequestration occurs in these patients needs to be understood. Here, Pakawat Chongsathidkiet, MD, of Duke University, Durham, NC, discusses the techniques being used to characterize the mechanism of action of this occurence in GBM, with the hopes of creating a strategy to reverse the effect of GBM on T-cells. This interview was recorded at the 2017 National Cancer Research Institute (NCRI) Conference, held in Liverpool, UK.
Characterizing a phenomenon in GBM patients who do not respond well to immunotherapy
